| Literature DB >> 34770942 |
Juraj Harmatha1, Miloš Buděšínský1, Zdeněk Zídek2, Eva Kmoníčková2,3.
Abstract
Saponins, a diverse group of natural compounds, offer an interesting pool of derivatives with biomedical application. In this study, three structurally related spirostanol saponins were isolated and identified from the leek flowers of Allium porrum L. (garden leek). Two of them were identical with the already known leek plant constituents: aginoside (1) and 6-deoxyaginoside (2). The third one was identified as new component of A. porrum; however, it was found identical with yayoisaponin A (3) obtained earlier from a mutant of elephant garlic Allium ampeloprasun L. It is a derivative of the aginoside (1) with additional glucose in its glycosidic chain, identified by MS and NMR analysis as (2α, 3β, 6β, 25R)-2,6-dihydroxyspirostan-3-yl β-D-glucopyranosyl-(1 → 3)-β-D-glucopranosyl-(1 → 2)-[β-D-xylopyranosyl-(1 → 3)]-β-D-glucopyranosyl]-(1 → 4)-β-D-galactopyranoside, previously reported also under the name alliporin. The leek native saponins were tested together with other known and structurally related saponins (tomatonin and digitonin) and with their related aglycones (agigenin and diosgenin) for in vitro cytotoxicity and for effects on NO production in mouse peritoneal cells. The highest inhibitory effects were exhibited by 6-deoxyaginoside. The obtained toxicity data, however, closely correlated with the suppression of NO production. Therefore, an unambiguous linking of obtained bioactivities of saponins with their expected immunobiological properties remained uncertain.Entities:
Keywords: Allium porrum; NO production; aginoside; alliporin; cytotoxicity; leek flowers; steroid saponins
Mesh:
Substances:
Year: 2021 PMID: 34770942 PMCID: PMC8587756 DOI: 10.3390/molecules26216533
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of Compounds 1–4 isolated from Allium porrum flowers.
Figure 2Schematic illustration of structural relations between the native leek-flower Compounds 1–4 and selected standard compounds 5–7. Related saponins 5 and 6, and aglycone 7 were selected for comparative bioactivity testing.
Figure 3Cytotoxicity (A) and NO inhibitory effects (B) of Compounds 1–7 in mouse peritoneal cells. (A) Compounds were applied at appropriate concentrations and cells were cultured for 24 h. LDH assay was used for viability evaluation. The results are expressed in optical density of untreated control or treated cells ± SEM of n = 8 values from two independent experiments. (B) The cells were treated with compounds for 24 h with or without LPS (lipopolysaccharide) and IFN-γ (interferon-gamma). The results represent the mean ± SEM of two independent experiments, n = 6.
Concentrations required for reducing the viability of cells and NO production by 50% (CC50 and IC50, respectively).
| Compound | Cytotoxicity CC50 (µM) | Nitric Oxide, IC50 (µM) |
|---|---|---|
| 11.13 (2.76–44.91) | 7.84 (2.16–28.51) | |
| 5.70 (1.83–17.71) | 5.21 (1.17–23.14) | |
| 7.21 (1.64–31.47) | 5.62 (1.59–19.24) | |
| >100 | >100 | |
| 5.83 (1.72–19.75) | 5.52 (1.57–19.46) | |
| 9.90 (2.80–35.03) | 7.19 (2.99–17.29) | |
| >100 | >100 |
13C and 1H NMR chemical shifts of compounds 1–4 in d5-pyridine .
| Position | Aginoside (1) | 6-Deoxyaginoside (2) | Alliporin (3) | Agigenin (4) | ||||
|---|---|---|---|---|---|---|---|---|
| Aglycone | 13C | 1H | 13C | 1H | 13C | 1H | 13C | 1H |
| 1 | 46.94 | 1.22; 2.18 | 45.38 | 1.12; 2.15 | 46.89 | 1.20; 2.17 | 48.10 | 1.37; 2.28 |
| 2 | 70.36 | 4.07 | 70.28 | 3.93 | 70.35 | 4.07 | 73.21 | 4.19 |
| 3 | 84.36 | 4.01 | 84.01 | 3.85 | 84.42 | 4.00 | 77.33 | 3.97 |
| 4 | 31.72 | 2.12; 2.36 | 33.83 | 1.43; 1.82 | 31.60 | 2.12; 2.36 | 35.10 | 2.10; 2.53 |
| 5 | 47.64 | 1.13 | 44.38 | 0.96 | 47.60 | 1.12 | 48.49 | 1.40 |
| 6 | 69.80 | 3.96 | 27.90 | 0.98; 1.11 | 69.79 | 3.95 | 70.31 | 4.09 |
| 7 | 40.67 | 1.13; 1.99 | 31.93 | 40.65 | 1.12; 1.98 | 40.88 | 1.21; 2.04 | |
| 8 | 29.83 | 2.14 | 34.37 | 1.33 | 29.80 | 2.13 | 30.08 | 2.23 |
| 9 | 54.32 | 0.71 | 54.15 | 0.53 | 54.30 | 0.69 | 54.75 | 0.83 |
| 10 | 36.84 | -- | 36.67 | -- | 36.81 | -- | 37.71 | -- |
| 11 | 21.16 | 1.35; 1.52 | 21.23 | 21.16 | 1.35; 1.50 | 21.46 | 1.47; 1.64 | |
| 12 | 39.90 | 1.04; 1.65 | 39.86 | 0.96; 1.59 | 39.90 | 1.05; 1.64 | 40.20 | 1.14; 1.71 |
| 13 | 40.50 | -- | 40.59 | -- | 40.47 | -- | 40.93 | -- |
| 14 | 56.03 | 1.10 | 56.13 | 0.98 | 56.02 | 1.08 | 56.29 | 1.16 |
| 15 | 32.04 | 1.40; 2.05 | 32.00 | 1.36; 1.98 | 32.03 | 1.40; 2.05 | 32.24 | 1.44; 2.10 |
| 16 | 80.95 | 4.55 | 80.98 | 4.53 | 80.94 | 4.53 | 81.11 | 4.56 |
| 17 | 62.82 | 1.81 | 62.79 | 1.76 | 62.79 | 1.80 | 63.04 | 1.85 |
| 18 | 16.40 | 0.82 | 16.42 | 0.77 | 16.38 | 0.81 | 16.62 | 0.87 |
| 19 | 17.01 | 1.25 | 13.22 | 0.66 | 16.98 | 1.24 | 17.55 | 1.44 |
| 20 | 41.82 | 1.91 | 41.80 | 1.91 | 41.79 | 1.90 | 41.99 | 1.95 |
| 21 | 14.83 | 1.12 | 14.83 | 1.10 | 14.82 | 1.10 | 15.03 | 1.14 |
| 22 | 109.09 | -- | 109.12 | -- | 109.08 | -- | 109.21 | -- |
| 23 | 31.58 | 1.56; 1.63 | 31.62 | 1.63 (2H) | 31.55 | 1.57; 1.63 | 31.74 | 1.60; 1.67 |
| 24 | 29.04 | 1.24; 1.54 | 29.08 | 1.23; 1.53 | 29.01 | 1.50 (2H) | 29.22 | 1.53 (2H) |
| 25 | 30.39 | 1.54 | 30.41 | 1.54 | 30.37 | 1.52 | 30.58 | 1.55 |
| 26 | 66.68 | 3.47; 3.57 | 66.70 | 3.48; 3.57 | 66.66 | 3.45; 3.55 | 66.83 | 3.49; 3.57 |
| 27 | 17.12 | 0.66 | 17.15 | 0.67 | 17.11 | 0.64 | 17.30 | 0.67 |
| Gal (I) | ||||||||
| 1 | 102.92 | 4.96 | 103.08 | 4.90 | 102.87 | 4.94 | ||
| 2 | 72.35 | 4.54 | 72.41 | 4.51 | 72.34 | 4.50 | ||
| 3 | 75.57 | 4.03 | 75.58 | 4.03 | 75.54 | 4.02 | ||
| 4 | 79.22 | 4.58 | 79.23 | 4.57 | 78.99 | 4.56 | ||
| 5 | 75.36 | 4.12 | 75.35 | 4.11 | 75.39 | 4.12 | ||
| 6 | 60.51 | 4.21; 4.59 | 60.50 | 4.20; 4.59 | 60.55 | 4.20; 4.57 | ||
| Glc (II) | ||||||||
| 1 | 104.45 | 5.19 | 104.52 | 5.18 | 104.66 | 5.13 | ||
| 2 | 81.05 | 4.33 | 81.06 | 4.33 | 80.94 | 4.53 | ||
| 3 | 86.83 | 4.11 | 86.81 | 4.11 | 86.89 | 4.06 | ||
| 4 | 70.19 | 3.77 | 70.22 | 3.78 | 70.11 | 3.76 | ||
| 5 | 77.40 | 3.83 | 77.42 | 3.82 | 77.33 | 3.80 | ||
| 6 | 62.72 | 4.04; 4.47 | 62.74 | 4.03; 4.47 | 62.65 | 4.04; 4.45 | ||
| Xyl (III) | ||||||||
| 1 | 104.76 | 5.23 | 104.78 | 5.23 | 104.11 | 5.16 | ||
| 2 | 74.94 | 3.94 | 74.96 | 3.94 | 74.99 | 4.05 | ||
| 3 | 78.27 | 3.90 | 78.30 | 3.90 | 78.23 | 3.84 | ||
| 4 | 70.60 | 4.10 | 70.62 | 4.09 | 70.47 | 4.07 | ||
| 5 | 67.12 | 3.65; 4.20 | 67.14 | 3.64; 4.20 | 67.01 | 3.62; 4.17 | ||
| Glc (IV) | ||||||||
| 1 | 104.59 | 5.57 | 104.62 | 5.57 | 103.68 | 5.57 | ||
| 2 | 75.87 | 4.04 | 75.92 | 4.03 | 75.28 | 3.92 | ||
| 3 | 77.98 | 4.14 | 77.98 | 4.13 | 87.70 | 4.10 | ||
| 4 | 71.20 | 4.04 | 71.20 | 4.08 | 69.54 | 3.86 | ||
| 5 | 78.50 | 4.07 | 78.52 | 4.07 | 77.83 | 4.12 | ||
| 6 | 62.54 | 4.40; 4.53 | 62.53 | 4.39; 4.54 | 62.26 | 4.20; 4.45 | ||
| Glc (V) | ||||||||
| 1 | 105.22 | 5.08 | ||||||
| 2 | 77.56 | 3.80 | ||||||
| 3 | 78.19 | 4.05 | ||||||
| 4 | 71.33 | 4.09 | ||||||
| 5 | 80.39 | 4.28 | ||||||
| 6 | 62.20 | 4.25; 4.40 | ||||||
Chemical shifts were referenced to the solvent signal (δH(3,5) = 7.20; δC(4) = 135.5), not determined value.
13C and 1H NMR data of alliporin (3) in CD3OD.
| Aglycone | Glycosidic Part | ||||
|---|---|---|---|---|---|
| Position | 13C | 1H | 13C | 1H | |
| 1 | 47.14 | H-1α: 0.93; H-1β: 1.905 | Gal (I) | ||
| 2 | 71.34 | 3.67 | 1 | 102.84 | 4.385 d ( |
| 3 | 85.02 | 3.56 | 2 | 72.86 | 3.72 dd ( |
| 4 | 31.47 | H-4α: 1.755; H-4β: 1.84 | 3 | 75.50 | 3.55 dd ( |
| 5 | 48.46 | 1.205 | 4 | 79.94 | 4.05 dd ( |
| 6 | 71.52 | 3.805 | 5 | 75.67 | 3.56 ddd (7.4; 6.3; 1.0) |
| 7 | 40.71 | H-7α: 1.185; H-4β: 1.83 | 6 | 61.40 | 3.86 dd ( |
| 8 | 30.74 | 1.95 | Glc (II) | ||
| 9 | 55.52 | 0.79 | 1 | 104.41 | 4.63 d ( |
| 10 | 37.77 | -- | 2 | 80.80 | 3.76 dd ( |
| 11 | 22.13 | H-11α: 1.57; H-11β: 1.44 | 3 | 87.59 | 3.74 dd ( |
| 12 | 41.02 | H-12α: 1.185; H-12β: 1.76 | 4 | 70.42 | 3.30 dd ( |
| 13 | 41.79 | -- | 5 | 70.25 | 3.46 ddd (9.8; 7.0; 2.3) |
| 14 | 57.13 | 1.18 | 6 | 63.04 | 3.90 dd ( |
| 15 | 32.70 | H-15α: 2.00; H-15β: 1.30 | Xyl (III) | ||
| 16 | 82.18 | 4.39 | 1 | 104.88 | 4.64 d ( |
| 17 | 63.83 | 1.76 | 2 | 75.31 | 3.26 dd ( |
| 18 | 16.98 | 0.829 | 3 | 75.47 | 3.29 dd ( |
| 19 | 17.24 | 1.073 | 4 | 70.96 | 3.53 ddd ( |
| 20 | 42.94 | 1.91 | 5 | 67.19 | 3.92 dd ( |
| 21 | 14.88 | 0.963 | Glc (IV) | ||
| 22 | 110.56 | -- | 1 | 103.70 | 5.01 d ( |
| 23 | 32.41 | H-23α: 1.70; H-23β: 1.57 | 2 | 75.01 | 3.42 dd ( |
| 24 | 29.88 | H-24α: 1.43; H-24β: 1.63 | 3 | 87.66 | 3.58 dd ( |
| 25 | 31.44 | 1.60 | 4 | 71.57 | 3.29 dd ( |
| 26 | 67.85 | H-26α: 3.32; H-26β:3.45 | 5 | 78.10 | 3.34 ddd ( |
| 27 | 17.49 | 0.794 | 6 | 62.87 | 3.92 ( |
| Glc (V) | |||||
| 1 | 105.21 | 4.57 d ( | |||
| 2 | 77.51 | 3.34 dd ( | |||
| 3 | 77.78 | 3.40 t ( | |||
| 4 | 77.96 | 3.345 dd (~9.0; 9.0) | |||
| 5 | 78.22 | 3.315 ddd ( | |||
| 6 | 62.63 | 3.89 dd ( | |||
Chemical shift referenced to the solvent signal (δH = 3.31, δC = 49.0).
Figure 4Selected NOE contacts (blue arrows) and 3J(C,H) (red arrows) observed in 2D-H,H-ROESY and 2D-H,C-HMBC spectra in CD3OD of alliporin, hereby identified as yayoisaponin A (3). (A) Aglycone: NOE contacts allow stereochemical assignment of methylene protons and prove the configuration at chiral centres. (B) Glycosidic part: NOE contacts and cross peaks in HMBC spectrum determining connection between hexapyranose units are shown. The 13C and 1H-NMR data are in Table 3.